

SYNB

Putnam BioRevolution ETF

Fund Description

SYNB actively invests in companies of all sizes around the globe that enable biological innovation.

FactSet Analyst Report

The security is being delisted. The last day of trading on an exchange is November 13, 2025. SYNB holds a high conviction portfolio that provides exposure to bio revolution, which involves technological advancements in the biological and life sciences that contribute to transforming the economy. The fund primarily invests in (i) technology enablers that provide the materials, equipment, and knowledge to enable biological production, (ii) disruptive biotech or synthetic bio companies, and (iii) other firms positioned to benefit from the theme. The funds exposure goes beyond healthcare, as it may also invest in other sectors that are likely to be positively impacted, such as consumer discretionary, consumer staples, materials, and agriculture. SYNB's portfolio typically comprises growth stocks. In selecting stocks, the fund manager considers valuation, financial strength, growth potential, industry position, projected future earnings, cash flows, and dividends.